|Bid||5,724.00 x 0|
|Ask||5,729.00 x 0|
|Day's Range||5,634.00 - 5,729.00|
|52 Week Range||4,761.00 - 7,183.00|
|Beta (5Y Monthly)||0.88|
|PE Ratio (TTM)||14.97|
|Earnings Date||May 10, 2021|
|Forward Dividend & Yield||106.00 (1.87%)|
|Ex-Dividend Date||Mar 30, 2021|
|1y Target Est||7,875.00|
Japan is making an aggressive move to grab enough coronavirus vaccine to inoculate its population four times over, a push the government hopes will instil confidence that it can host a delayed summer Olympics next year. Like other rich countries, Japan is signing multiple deals because some of the vaccines could fail in clinical trials or require more than one dose, an approach some experts consider prudent. Chief Cabinet Secretary Yoshihide Suga, the top government spokesman, said Japan was working with Olympic organisers on how to go ahead with the Games, tying the effort to the need to secure a vaccine.
Britain's GSK said on Tuesday that an injection of its cabotegravir drug given every two months was found to be 66% more effective in preventing HIV infections than Gilead's Truvada daily oral pills. HIV incidence rate - or the number of people who contract the infection in a period - was 0.41% with the injection, compared with 1.22% with Gilead's Truvada, final data from a study presented at the virtual AIDS conference showed. Truvada is currently the standard of care for preventing HIV, but GSK hopes to challenge its dominance by making shorter, long-lasting regimens and less toxic alternatives through its ViiV Healthcare unit.
The U.S. Food and Drug Administration has approved a drug to treat infants and children with HIV, with the drug having been developed by drugmaker GlaxoSmithKline's HIV drugs division ViiV Healthcare, the FDA and the GSK unit said. The FDA said on Friday it was granting Viiv the approval of Tivicay and Tivicay PD tablets "for suspension to treat HIV-1 infection in pediatric patients at least four weeks old and weighing at least 3 kgs in combination with other antiretroviral treatments". The drug is currently under review by the European Medicines Agency, ViiV, in which Pfizer and Shionogi have small stakes, said in a separate statement.